Cargando…

Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study

Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertlich, Mattis, Freytag, Saskia, Dombrowski, Tobias, Jurmeister, Philipp, Spiegel, Jennifer Lee, Bertlich, Ines, Ihler, Friedrich, Weiss, Bernhard G., Haubner, Frank, Gröger, Moritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666224/
https://www.ncbi.nlm.nih.gov/pubmed/36397403
http://dx.doi.org/10.1097/MD.0000000000031031
_version_ 1784831455776473088
author Bertlich, Mattis
Freytag, Saskia
Dombrowski, Tobias
Jurmeister, Philipp
Spiegel, Jennifer Lee
Bertlich, Ines
Ihler, Friedrich
Weiss, Bernhard G.
Haubner, Frank
Gröger, Moritz
author_facet Bertlich, Mattis
Freytag, Saskia
Dombrowski, Tobias
Jurmeister, Philipp
Spiegel, Jennifer Lee
Bertlich, Ines
Ihler, Friedrich
Weiss, Bernhard G.
Haubner, Frank
Gröger, Moritz
author_sort Bertlich, Mattis
collection PubMed
description Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS.
format Online
Article
Text
id pubmed-9666224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96662242022-11-16 Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study Bertlich, Mattis Freytag, Saskia Dombrowski, Tobias Jurmeister, Philipp Spiegel, Jennifer Lee Bertlich, Ines Ihler, Friedrich Weiss, Bernhard G. Haubner, Frank Gröger, Moritz Medicine (Baltimore) 6000 Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666224/ /pubmed/36397403 http://dx.doi.org/10.1097/MD.0000000000031031 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 6000
Bertlich, Mattis
Freytag, Saskia
Dombrowski, Tobias
Jurmeister, Philipp
Spiegel, Jennifer Lee
Bertlich, Ines
Ihler, Friedrich
Weiss, Bernhard G.
Haubner, Frank
Gröger, Moritz
Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title_full Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title_fullStr Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title_full_unstemmed Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title_short Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
title_sort subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study
topic 6000
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666224/
https://www.ncbi.nlm.nih.gov/pubmed/36397403
http://dx.doi.org/10.1097/MD.0000000000031031
work_keys_str_mv AT bertlichmattis subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT freytagsaskia subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT dombrowskitobias subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT jurmeisterphilipp subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT spiegeljenniferlee subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT bertlichines subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT ihlerfriedrich subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT weissbernhardg subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT haubnerfrank subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy
AT grogermoritz subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy